Last updated: 2026-09-04 20:58:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Mainz Biomed N.V. (MYNZ) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Mainz Biomed N.V. (MYNZ) is trading at $-- in after-hours trading as of --, -- from the regular-session close of $--.
After-hours trading shows how investors are pricing MYNZ after the regular session closes. The current after-hours price is -- the regular-session close, indicating -- after-hours sentiment.
Over the past seven days, Mainz Biomed N.V. (MYNZ) moved from $0,74 to $0,84, representing a gain of 14,35% ($0,11).
The stock traded between $0,68 and $0,94 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 897,98 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mainz Biomed N.V. (MYNZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.